Risk Factors for Heart Failure Among Pan-European Childhood Cancer Survivors: A PanCareSurFup and ProCardio Cohort and Nested Case-Control Study.
Esmée C de BaatElizabeth Arnoldina Maria FeijenRaoul C ReulenRodrigue Setcheou AllodjiFrancesca BagnascoEdit BárdiFabiën Naomi BelleJulianne ByrneElvira C van DalenGhazi DebicheIbrahima DialloDesiree GrabowLars HjorthMomcilo JankovicClaudia Elisabeth KuehniGill LevittDamien LlanasJacqueline LoonenLorna Zadravec ZaletelMilena M MauleLucia MiligiHelena J H Van der PalCécile M RonckersCarlotta SacerdoteRoderick SkinnerZsuzsanna JakabCristina VeresNadia HaddyDavid L WinterFlorent de VathaireMichael M HawkinsLeontien C M KremerPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
total cumulative anthracycline dose have no significantly increased risk of HF. These new findings might have consequences for new treatment protocols for children with cancer and for cardiomyopathy surveillance guidelines.